Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Prostatic Neoplasms 5Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Colonic Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Tooth, Impacted 1Testicular Neoplasms 1Smoldering Multiple Myeloma 1Oropharyngeal Neoplasms 1Neuroblastoma 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Melanoma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Hepatoblastoma 1Hematologic Neoplasms 1Hemangioma, Cavernous, Central Nervous System 1Hemangioma, Cavernous 1Ganglioneuroblastoma 1Fibrolamellar hepatocellular carcinoma 1Esophageal Neoplasms 1Epstein-Barr Virus Infections 1Carcinoma, Renal Cell 1Breast Carcinoma In Situ 1Anus Neoplasms 1Anal Canal Carcinoma 1

Interventions

pembrolizumab 1dehydroftorafur 1Watchful Waiting 1Taxes 1Restraint, Physical 1Radiotherapy, Intensity-Modulated 1Platinum 1Paclitaxel 1Matrix-M 1Gemcitabine 1Fluorouracil 1Cisplatin 1Bevacizumab 1AP 1903 reagent 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Epstein-Barr Virus Infections × Watchful Waiting × Clear all
NCT02135042 2026-05-07

Individualized Treatment Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

NRG Oncology

Phase 2/3 Active not recruiting
685 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡